Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Ahmed S, et al. Among authors: mussetti a. Biol Blood Marrow Transplant. 2019 Sep;25(9):1859-1868. doi: 10.1016/j.bbmt.2019.05.025. Epub 2019 May 25. Biol Blood Marrow Transplant. 2019. PMID: 31132455 Free PMC article. Clinical Trial.
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Montefusco V, Spina F, Patriarca F, Offidani M, Bruno B, Montanari M, Mussetti A, Sperotto A, Scortechini I, Dodero A, Fanin R, Valagussa P, Corradini P. Montefusco V, et al. Among authors: mussetti a. Biol Blood Marrow Transplant. 2013 Mar;19(3):424-8. doi: 10.1016/j.bbmt.2012.10.032. Epub 2012 Nov 8. Biol Blood Marrow Transplant. 2013. PMID: 23142330 Free article. Clinical Trial.
Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M; Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Bachanova V, et al. Among authors: mussetti a. Biol Blood Marrow Transplant. 2015 Sep;21(9):1605-11. doi: 10.1016/j.bbmt.2015.05.007. Epub 2015 May 14. Biol Blood Marrow Transplant. 2015. PMID: 25983043 Free PMC article. Clinical Trial.
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Klyuchnikov E, et al. Among authors: mussetti a. Biol Blood Marrow Transplant. 2015 Dec;21(12):2091-2099. doi: 10.1016/j.bbmt.2015.07.028. Epub 2015 Aug 4. Biol Blood Marrow Transplant. 2015. PMID: 26253007 Free PMC article.
Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.
Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M. Klyuchnikov E, et al. Among authors: mussetti a. Bone Marrow Transplant. 2016 Jan;51(1):58-66. doi: 10.1038/bmt.2015.223. Epub 2015 Oct 5. Bone Marrow Transplant. 2016. PMID: 26437062 Free PMC article. Clinical Trial.
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M. Kanate AS, et al. Among authors: mussetti a. Blood. 2016 Feb 18;127(7):938-47. doi: 10.1182/blood-2015-09-671834. Epub 2015 Dec 15. Blood. 2016. PMID: 26670632 Free PMC article. Clinical Trial.
Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors.
Mussetti A, Kernan NA, Prockop SE, Scaradavou A, Lehrman R, Ruggiero JM, Curran K, Kobos R, O'Reilly R, Boulad F. Mussetti A, et al. Pediatr Hematol Oncol. 2016 Sep;33(6):347-358. doi: 10.1080/08880018.2016.1204399. Epub 2016 Oct 7. Pediatr Hematol Oncol. 2016. PMID: 27715384 Free PMC article.
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.
Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A, Barretta F, Terruzzi E, Mussetti A, Pini M, Bosi A, Dominietto A, Cascavilla N, Onida F, Narni F, Farina L, Rambaldi A, Corradini P. Dodero A, et al. Among authors: mussetti a. Biol Blood Marrow Transplant. 2017 Jul;23(7):1102-1109. doi: 10.1016/j.bbmt.2017.03.031. Epub 2017 Apr 5. Biol Blood Marrow Transplant. 2017. PMID: 28390983 Free article. Clinical Trial.
90 results